Fortress Biotech (FBIO) Cash from Operations Growth (3y) (2013 - 2025)
Powered by 
Analysis
Fortress Biotech (FBIO) Cash from Operations Growth (3y) (2013 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | -0.27% |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | -7.35% |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | 16.85% |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | - |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | 52.90% |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | 96.08% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 6.22% |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 10.23% |
| 10 | Fortress Biotech | 86.15 Mn | -110.42 Mn | 12.58 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 36.00% |
| Sep 30, 2025 | 47.93% |
| Jun 30, 2025 | 12.70% |
| Mar 31, 2025 | 25.26% |
| Dec 31, 2024 | 30.65% |
| Sep 30, 2024 | 2.58% |
| Jun 30, 2024 | 14.11% |
| Mar 31, 2024 | -5.39% |
| Dec 31, 2023 | -19.47% |
| Sep 30, 2023 | 11.11% |
| Jun 30, 2023 | -24.12% |
| Mar 31, 2023 | -25.45% |
| Dec 31, 2022 | -24.07% |
| Sep 30, 2022 | -38.57% |
| Jun 30, 2022 | -13.51% |
| Mar 31, 2022 | -22.77% |
| Dec 31, 2021 | -20.42% |
| Sep 30, 2021 | 4.31% |
| Jun 30, 2021 | -12.69% |
| Mar 31, 2021 | 7.99% |